Petosemtamab clinical trials
Also written MCLA-158.
How each study uses petosemtamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the petosemtamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2024 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1) · Folfox protocol (1)
Studies
Open first, then newest update. How each study uses petosemtamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)RecruitingPhase 3GenmabNCT07775287Written as Petosemtamab
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)RecruitingPhase 3GenmabNCT07702032Written as Petosemtamab
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingPhase 1/2GenmabNCT03526835Written as MCLA-158
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Active, not recruitingPhase 3GenmabNCT06496178Written as Petosemtamab
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingPhase 3GenmabNCT06525220Written as Petosemtamab
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnPhase 2GenmabNCT07353957Written as Petosemtamab + Pembrolizumab
Codes
What other systems call petosemtamab · ClinicalTrials.gg INT018662
- UNII (FDA) Z6Z6IVE7W4PETOSEMTAMABOne source FDA
- NCI Thesaurus C174952PetosemtamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z6Z6IVE7W4 | PETOSEMTAMAB | One source FDA |
| NCI Thesaurus | C174952 | Petosemtamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.